IT firm Cognizant has inked a multi-year agreement with pharmaceutical company AstraZeneca to deliver comprehensive biostatistics and medical reporting services for generating clinical study reports. No financial details, however, were disclosed.
Under the agreement, the IT firm will provide centralised statistical programming, statistical analysis, medical writing, and document publishing services across the entire chain of clinical data reporting from case report forms to clinical study reports, Cognizant said in a statement.
This will enable AstraZeneca to increase operational efficiency, reduce cycle times, and optimise costs, it added.
AstraZeneca will continue to own and manage key scientific and medical activities associated with the design of clinical trial programmes, and the interpretation of data from them.
“Cognizant will help us streamline our clinical development operations. This is key to our business transformation aimed at achieving greater efficiency, agility, flexibility and global competitiveness — all of which are crucial to clinical trials and development of new drugs,” AstraZeneca VP and Head of Clinical Development Karin Wingstrand said.
The agreement further expands the services that Cognizant provides to AstraZeneca.